Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Meningiomas are the most common primary intracranial tumors in adults and are increasing
in incidence due to the aging population and increased access to neuroimaging. While most …
in incidence due to the aging population and increased access to neuroimaging. While most …
Targeting histone deacetylase 6 (HDAC6) to enhance radiation therapy in meningiomas in a 2D and 3D in vitro study
J Na, S Shaji, CO Hanemann - EBioMedicine, 2024 - thelancet.com
Background External radiation therapy (RT) is often a primary treatment for inoperable
meningiomas in the absence of established chemotherapy. Histone deacetylase 6 (HDAC6) …
meningiomas in the absence of established chemotherapy. Histone deacetylase 6 (HDAC6) …
[HTML][HTML] Investigating the radiobiological response to peptide receptor radionuclide therapy using patient-derived meningioma spheroids
TGA Reuvers, V Grandia, RMC Brandt, M Arab… - Cancers, 2024 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is a potential new treatment
option for patients with meningiomas, the most common form of adult intracranial brain …
option for patients with meningiomas, the most common form of adult intracranial brain …
Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours
F Dave, K Herrera, A Lockley, LL van de Weijer… - Oncogene, 2024 - nature.com
Meningioma and schwannoma are common tumours of the nervous system. They occur
sporadically or as part of the hereditary NF2-related schwannomatosis syndrome. There is …
sporadically or as part of the hereditary NF2-related schwannomatosis syndrome. There is …
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models
S Bhattacharyya, JL Oblinger… - Neuro-Oncology …, 2024 - academic.oup.com
Background NF2-associated meningiomas are progressive, highly morbid, and
nonresponsive to chemotherapies, highlighting the need for improved treatments. We have …
nonresponsive to chemotherapies, highlighting the need for improved treatments. We have …
[HTML][HTML] Unlocking Brigatinib's Potential: A Remarkable Case of Drug Repurposing in NF2-SWN
Synodos for NF2 is a collaborative research initiative aimed at accelerating the development
of treatments for NF2-related schwannomatosis, a complex and rare genetic disorder …
of treatments for NF2-related schwannomatosis, a complex and rare genetic disorder …